Amo Pharma Partners in Rare DiseasesBy
Amo Pharma, a London-based privately held biopharmaceutical company, has entered into a collaboration agreement with Ranedis Pharmaceuticals, a Philadelphia-based privately held biopharmaceutical company, to progress the development of a drug candidate for rare genetic diseases, including certain lysosomal storage disorders and other diseases affecting the central nervous system.
With the agreement, Ranedis has granted Amo an exclusive option to acquire the worldwide rights to the drug candidate, RND-001, during the collaboration period. RND-001 is a formulation of a histone deacetylase inhibitor (HDACi) whose properties allow for delivery of the molecule to the brain. Amo and Ranedis will research a range of applications in the treatment of rare diseases including certain neurodegenerative diseases. Terms of the deal were not disclosed.
Source: Amo Pharma